The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Larina V.N.

Pirogov Russian National Research Medical University

Shcherbina E.S.

Institute of Clinical Medicine of the Pirogov Russian National Research Medical University (Pirogov University)

One to One

Authors:

Larina V.N., Shcherbina E.S.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2025;(11): 26‑30

Read: 173 times

To cite this article:

Larina VN, Shcherbina ES. One to One. Non Nocere. New Therapeutic Journal. 2025;(11):26‑30. (In Russ.)

References:

  1. Polyakov D.S., Fomin I.V., Belenkov Yu.N., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14.  https://doi.org/10.18087/cardio.2021.4.n1628
  2. Belaya Zh.E., Belova K.Yu., Biryukova E.V., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4-47. (In Russ.) https://doi.org/10.14341/osteo12930
  3. James SL, Lucchesi LR, Bisignano C, et al. The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017. Inj Prev. 2020 Oct;26(Supp 1):i3–i11.  https://doi.org/10.1136/injuryprev-2019-043286
  4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. https://doi.org/10.1093/eurheartj/ehw210
  5. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1):136.  https://doi.org/10.1007/s11657-013-0136-1
  6. Topolyanskaya S.V., Osipovskaya I.O., Lifanova L.S., Eliseeva T.A., Vakulenko O.N. Mineral density and metabolism of bone tissue in patients with chronic heart failure insufficiency of senior age. The Russian Archives of Internal Medicine. 2017;7(3):205-211. (In Russ.) https://doi.org/10.20514/2226-6704-2017-7-3-205-211
  7. Liu XP, Jian XY, Liang DL, et al. The association between heart failure and risk of fractures: Pool analysis comprising 260,410 participants. Front Cardiovasc Med. 2022 Oct 14;9:977082. https://doi.org/10.3389/fcvm.2022.977082
  8. Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J, et al. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. JBMR Plus. 2019 May 13;3(9):e10192. https://doi.org/10.1002/jbm4.10192
  9. Skripnikova I.A., Kolchina M.A., Meshkov A.N., Kiseleva A.V., Drapkina O.M. Arterial calcification, atherosclerosis and osteoporosis: only clinical associations or a genetic platform? Cardiovascular Therapy and Prevention. 2021;20(7):3034. (In Russ.) https://doi.org/10.15829/1728-8800-2021-3034
  10. Larina V.N., Shcherbina E.S., Dryutova V.V., Larin V.G. Comorbidity of chronic heart failure and osteoporosis: literature review. CardioSomatics. 2023;4(2):93-104.  https://doi.org/10.17816/CS375321
  11. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31.  https://doi.org/10.1093/ageing/afy169
  12. Papadopoulou SK, Tsintavis P, Potsaki P, Papandreou D. Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis. J Nutr Health Aging. 2020;24(1):83-90.  https://doi.org/10.1007/s12603-019-1267-x
  13. Emami A, Saitoh M, Valentova M, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail. 2018 Nov;20(11):1580-1587. https://doi.org/10.1002/ejhf.1304
  14. Kara M, Özçakar L. Sarcopenia, osteoporosis, and fractures: what we see mainly depends on how we look? Osteoporos Int. 2023 Feb;34(2):425-426.  https://doi.org/10.1007/s00198-022-06418-7
  15. Zhu Y, Zeng Q, Shi Y, et al. Association between sarcopenia and osteoporosis: the cross-sectional study from NHANES1999-2020 and a bi-directions Mendelian randomization study. Front Endocrinol (Lausanne). 2024 Oct 8;15:1399936. https://doi.org/10.3389/fendo.2024.1399936
  16. Mikaelyan A.A., Varaeva Yu.R., Liskova Yu.V., et al. Sarcopenia and chronic heart failure. Part 1. General Medicine. 2023;2:51-56.  https://doi.org/10.24412/2071-5315-2023-12879
  17. Drapkina O.M., Skripnikova I.A., Yaralieva E.K., Myasnikov R.P. Body composition in patients with heart failure. Cardiovascular Therapy and Prevention. 2022;21(12):3451. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3451
  18. Topolyanskaya S.V. Sarcopenia, obesity, osteoporosis and old age. Sechenov Medical Journal. 2020; 11(4):23-35.  https://doi.org/10.47093/2218-7332.2020.11.4.23-35
  19. Koutroumpakis E, Kaur R, Taegtmeyer H, Deswal A. Obesity and Heart Failure with Preserved Ejection Fraction. Heart Fail Clin. 2021 Jul;17(3):345-356.  https://doi.org/10.1016/j.hfc.2021.02.003
  20. Ballyuzek MF, Mashkova MV. Cachexia syndrome: The present state of the problem and importance in clinical practice. Therapeutic Archive. 2015;87(8):111-118. (In Russ.) https://doi.org/10.17116/terarkh2015878111-118
  21. Gaudio A, Xourafa A, Rapisarda R, Castellino P, Signorelli SS. Peripheral artery disease and osteoporosis: Not only age-related (Review). Mol Med Rep. 2018 Dec;18(6):4787-4792. https://doi.org/10.3892/mmr.2018.9512
  22. Spoladore R, Ciampi CM, Ossola P, et al. Heart Failure and Osteoporosis: Shared Challenges in the Aging Population. J Cardiovasc Dev Dis. 2025 Feb 13;12(2):69.  https://doi.org/10.3390/jcdd12020069
  23. Bandeira F, Oliveira LB, Caldeira RB, Toscano LS. Skeletal consequences of heart failure. Womens Health (Lond). 2022 Jan–Dec;18:17455057 221135501. https://doi.org/10.1177/17455057221135501
  24. Hanna A, Frangogiannis NG. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. Cardiovasc Drugs Ther. 2020 Dec;34(6):849-863.  https://doi.org/10.1007/s10557-020-07071-0
  25. Bolla GB, Fedele A, Faggiano A, Sala C, Santangelo G, Carugo S. Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC Cardiovasc Disord. 2022 May 13;22(1):217.  https://doi.org/10.1186/s12872-022-02647-0
  26. Crispino SP, Segreti A, Nafisio V, et al. The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure. Biomedicines. 2025 Mar 3;13(3):608.  https://doi.org/10.3390/biomedicines13030608

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.